[1]张运涛,宋丽梅.钙神经蛋白抑制剂对糖尿病肾病的治疗效果及对肾脏炎症调节作用的影响[J].医学信息,2021,34(04):145-147.[doi:10.3969/j.issn.1006-1959.2021.04.039]
　ZHANG Yun-tao,SONG Li-mei.The Therapeutic Effect of Calcineurin Inhibitor on Diabetic Nephropathy and Its Influence on the Regulation of Renal Inflammation[J].Medical Information,2021,34(04):145-147.[doi:10.3969/j.issn.1006-1959.2021.04.039]
点击复制

钙神经蛋白抑制剂对糖尿病肾病的治疗效果及对肾脏炎症调节作用的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年04期
页码:
145-147
栏目:
临床研究
出版日期:
2021-02-15

文章信息/Info

Title:
The Therapeutic Effect of Calcineurin Inhibitor on Diabetic Nephropathy and Its Influence on the Regulation of Renal Inflammation
文章编号:
1006-1959（2021）04-0145-03
作者:
张运涛; 宋丽梅
（天津市南开区三潭医院内科，天津 300000）
Author(s):
ZHANG Yun-tao; SONG Li-mei
(Department of Internal Medicine,Santan Hospital,Nankai District,Tianjin 300000,China)
关键词:
钙神经蛋白抑制剂; 糖尿病肾病; 血清胱抑素C
Keywords:
Calcineurin inhibitor; Diabetic nephropathy; Serum cystatin C
分类号:
R69
DOI:
10.3969/j.issn.1006-1959.2021.04.039
文献标志码:
A
摘要:
目的 研究钙神经蛋白抑制剂对糖尿病肾病治疗效果及对肾脏炎症调节作用的影响。方法 选取2018年10月~2019年10月我院诊治的94例糖尿病肾病患者为研究对象，采用随机数字表法分为对照组和观察组，各47例。对照组采用常规治疗及对症治疗，观察组在对照组基础上采用钙神经蛋白抑制剂治疗，比较两组临床治疗总有效率、空腹血糖（FBG）、肾功能指标[血肌酐（Scr）、尿素氮（BUN）、血清胱抑素C（Cys C）、尿24h肌酐清除率（24hCcr）]、炎症因子[尿肾小球转化因子β（TGF-β）、炎症小体（NLRP3）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、尿单核细胞趋化蛋白（MCP-1）]水平。结果 观察组治疗总有效率为95.74%，高于对照组的85.11%，差异有统计学意义（P＜0.05）；治疗后，观察组FBG低于对照组，差异有统计学意义（P＜0.05）；观察组Scr、BUN、Cys C低于对照组，24hCcr高于对照组，差异有统计学意义（P＜0.05）；观察组尿TGF-β、NLRP3、IL-6、TNF-α、尿MCP-1低于对照组，差异有统计学意义（P＜0.05）；在治疗和观察期间，两组均未发生严重不良反应。结论 钙神经蛋白抑制剂可提高糖尿病肾病治疗效果，改善肾功能指标，降低炎症因子水平，抑制肾炎症反应，减轻肾脏炎症调节作用，进一步促进肾功能恢复，且临床应用安全性良好。
Abstract:
Objective To study the effect of calcineurin inhibitor on the treatment of diabetic nephropathy and its influence on the regulation of renal inflammation.Methods 94 patients with diabetic nephropathy diagnosed and treated in our hospital from October 2018 to October 2019 were selected as the research objects. They were divided into control group and observation group by random number table method, with 47 cases in each group.The control group was treated with conventional and symptomatic treatment, and the observation group was treated with calcineurin inhibitors on the basis of the control group. The two groups were compared with the total effective rate of clinical treatment, fasting blood glucose (FBG), renal function indicators [serum creatinine (Scr), urea Nitrogen (BUN), serum cystatin C (Cys C), urine 24h creatinine clearance (24hCcr)], inflammatory factors [urinary glomerular transforming factor β(TGF-β), inflammasome (NLRP3),Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), urinary monocyte chemoattractant protein (MCP-1)] levels.Results The total effective rate of treatment in the observation group was 95.74%, which was higher than 85.11% in the control group,the difference was statistically significant (P<0.05);After treatment, the FBG of the observation group was lower than that of the control group, the difference was statistically significant (P＜0.05);The Scr, BUN and Cys C of the observation group were lower than those of the control group, and the 24h Ccr was higher than the control group, the difference was statistically significant (P<0.05);The urine TGF-β, NLRP3, IL-6, TNF-α, and urine MCP-1 in the observation group were lower than those in the control group,the difference was statistically significant (P<0.05);During the treatment and observation period, no serious adverse reactions occurred in the two groups.Conclusion Calneurin inhibitors can improve the therapeutic effect of diabetic nephropathy, improve renal function indexes, reduce the level of inflammatory factors, inhibit renal inflammation, reduce the regulation of renal inflammation, and further promote the recovery of renal function. It is safe for clinical application.

参考文献/References:

[1]Li B,Liu S,Miao L,et al.Prevention of diabetic complications by activation of Nrf2:diabetic cardiomyopathy and nephropathy[J].Exp Diabetes Res,2012(2012):216512. [2]谢丽君,廖蕴华.特发性膜性肾病的分子发病机制[J].中华肾病研究电子杂志,2015,4(6):33-39 . [3]Kumar B,Kowluru A,Kowluru RA.Lipotoxicity augments glucotoxicity-induced mitochondrial damage in the development of diabetic retinopathy[J].Invest Ophthalmol Vis Sci,2015,56(5):2985-2992. [4]刘志红,吴青,黎磊石,等.膜性肾病患者足细胞钙神经蛋白表达的检测及其临床意义[J].肾脏病与透析肾移植杂志,2015,19(1):3-11. [5]李泽宇,刘栋,袁文明,等.糖尿病肾病危险因素及血压控制临界值研究[J].中国全科医学,2014(20):2325-2328. [6]杨涛.雷公藤多苷片联合缬沙坦治疗早期糖尿病肾病临疗效[J].青岛医药卫生,2013,45(4):270-271. [7]陈忠英,巨超龙.血清胱抑素C、β2微球蛋白及尿微量清蛋白与尿肌酐比值在早期２型糖尿病肾病患者诊断中的临床意义[J].陕西医学杂志,2017,46(4):467-468. [8]热孜万古丽·阿布都拉,宋雪.厄贝沙坦联合阿托伐他汀治疗对早期糖尿病肾病患者血清Cys－C、Hcy、TNF-α、ET、TGF-b1水平的影响[J].海南医学院学报,2017,23(20):2776-2778. [9]Vu Manh TP,Bertho N,Hosmalin A,et al.Investigating Evolutionary Conservation of Dendritic Cell Subset Identity and Functions[J].Front Immunol,2015(6):260. [10]王世英,孙志强,陈宝平.2型糖尿病肾病患者治疗前后血清胱抑素C和β2微球蛋白变化的临床意义研究[J].中国实用医刊,2016,43(2):3-4. [11]郑锦顺.阿托伐他汀联合厄贝沙坦对早期糖尿病肾病患者胱抑素C和脂联素水平的影响[J].河南医学研究,2015,24(7):68-69. [12]赵换牢,支亚军.松龄血脉康胶囊联合厄贝沙坦片对高血压合并糖尿病肾病患者血清RBP-4、COMP、APN及ghrelin的影响[J].现代中西医结合杂志,2018,27(23):2565-2569. [13]邴兆伟,陈斌.达格列净联合厄贝沙坦治疗糖尿病肾病的临床疗效[J].医学综述,2018,24(23):4763-4767． [14]王丽群,王筱景,楼江涌.阿托伐他汀联合厄贝沙坦治疗早期糖尿 病肾病疗效观察及对血清胱抑素C和脂联素水平的影响[J].中国基层医药,2015,22(22):3437-3439. [15]巩卓.达格列净联合厄贝沙坦治疗糖尿病肾病的临床分析[J].糖尿病新世界,2019,14(1):173-174. [16]东珍,于秋红,谷晓宁.丹红注射液联合厄贝沙坦对糖尿病肾病患者氧化应激反应,肾功能损害的影响[J].海南医学院学报,2017,23(15):2052-2055.

相似文献/References:

[1]陈淑雯.肾衰宁联合科素亚治疗早期糖尿病肾病的临床观察[J].医学信息,2018,31(05):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
　CHEN Shu-wen.Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu[J].Medical Information,2018,31(04):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
[2]何丽杰.中西医治疗糖尿病肾病的临床效果分析[J].医学信息,2018,31(10):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
　HE Li-jie.Clinical Effect Analysis of Diabetic Nephropathy Treated by Chinese and Western Medicine[J].Medical Information,2018,31(04):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
[3]贺 伟,高 峰.24 h尿微量白蛋白、血清胱抑素C水平与血清肌酐、尿素水平在2型糖尿病肾病早期诊断的意义[J].医学信息,2018,31(11):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
　HE Wei,GAO Feng.The Significance of 24 h Urinary Microalbumin,Serum Cystatin C and Serum Creatinine and Urea Levels in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Medical Information,2018,31(04):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
[4]黄秋菊.胱抑素C及脂蛋白α在早期糖尿病肾病诊断中的价值研究[J].医学信息,2018,31(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
　HUANG Qiu-ju.The Value of Cystatin C and Lipoprotein α in the Diagnosis of Early Diabetic Nephropathy[J].Medical Information,2018,31(04):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
[5]陆新虹,温玉洁,胡 欣,等.α-硫辛酸对2型糖尿病肾病患者 血清内脂素的影响研究[J].医学信息,2018,31(14):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
　LU Xin-hong,WEN Yu-jie,HU Xin,et al.Effect of α-lipoic Acid on Serum Visfatin in Patients with Type 2 Diabetic Nephropathy[J].Medical Information,2018,31(04):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
[6]肖学秀.益气活血汤联合西药治疗早期糖尿病肾病的临床观察[J].医学信息,2019,32(02):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
　XIAO Xue-xiu.Clinical Observation of Yiqi Huoxue Decoction Combined with Western Medicine in Treating Earlyn Diabetic Nephropathy[J].Medical Information,2019,32(04):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
[7]郑小鹏,辛 华.糖尿病肾病研究进展[J].医学信息,2018,31(16):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
　ZHENG Xiao-peng,XIN Hua.Progress in the Study of Diabetic Nephropathy[J].Medical Information,2018,31(04):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
[8]李志俊,王 利,王 浩.姜黄素改善糖尿病肾病的作用机制研究[J].医学信息,2018,31(24):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
　LI Zhi-jun,WANG Li,WANG Hao.Study on the Mechanism of Curcumin in Improving Diabetic Nephropathy[J].Medical Information,2018,31(04):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
[9]张国艳,张佳田,隋洪玉.糖尿病肾病大鼠动物模型建立及INF-α干预机制研究[J].医学信息,2019,32(05):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
　ZHANG Guo-yan,ZHANG Jia-tian,SUI Hong-yu.Establishment of Animal Model of Diabetic Nephropathy Rats and Study of INF-α Intervention Mechanism[J].Medical Information,2019,32(04):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
[10]吴怡琪,卢 文.皮肤AGEs荧光检测对糖尿病肾病的临床意义[J].医学信息,2019,32(06):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]
　WU Yi-qi,LU Wen.Clinical Significance of Skin AGEs Fluorescence Detection in Diabetic Kidney Disease[J].Medical Information,2019,32(04):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]

更新日期/Last Update: 1900-01-01